Pancreatic cancer medical therapy: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 18: Line 18:
===Chemotherapy===
===Chemotherapy===


In patients not suitable for resection with curative intent, palliative [[chemotherapy]] may be used to improve quality of life and gain a modest survival benefit. [[Gemcitabine]] was approved by the US [[FDA]] in 1998 after a clinical trial reported improvements in [[quality of life]] in patients with advanced pancreatic cancer.  This marked the first FDA approval of a chemotherapy drug for a non-survival [[clinical trial]] endpoint. Gemcitabine is administered intravenously on a weekly basis. Addition of [[oxaliplatin]] (Gem/Ox) conferred benefit in small trials, but is not yet standard therapy.<ref name="pmid16434988">{{cite journal |author=Demols A, Peeters M, Polus M, ''et al'' |title=Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study |journal=Br. J. Cancer |volume=94 |issue=4 |pages=481–5 |year=2006 |pmid=16434988 |doi=10.1038/sj.bjc.6602966}}</ref> [[Fluorouracil]] (5FU) may also be included.
:*Drugs Approved for Pancreatic Cancer


On the basis of a Canadian led Phase III Randomised Controlled trial involving 569 patients with advanced pancreatic cancer, the US FDA has licensed the use of [[erlotinib]] (Tarceva) in combination with [[gemcitabine]] as a palliative regimen for pancreatic cancer. This trial compared the action of gemcitabine/erlotinib vs gemcitabine/placebo and demonstrated improved survival rates, improved tumor response and improved progression-free survival rates.  The survival improvement with the combination is on the order of less than four weeks, leading some [[cancer]] experts to question the incremental value of adding [[erlotinib]] to [[gemcitabine]] treatment.  New trials are now investigating the effect of the above combination in the adjuvant and neoadjuvant setting.<ref>[http://www.fda.gov/ohrms/dockets/AC/05/briefing/2005-4174B1_03_01-OSI-Tarceva.pdf#search=%22%20fda%20erlotinib%20pancreatic%22 FDA approval briefing]</ref> A trial of anti-angiogenesis agent [[bevacizumab]] (Avastin) as an addition to chemotherapy has shown no improvement in survival of patients with advanced pancreatic cancer. It may cause higher rates of high blood pressure, bleeding in the stomach and intestine, and intestinal perforations.
::*Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
::*Adrucil (Fluorouracil)
 
::*Afinitor (Everolimus)
::*Efudex (Fluorouracil)
::*Erlotinib Hydrochloride
::*Everolimus
::*Fluoroplex (Fluorouracil)
::*Fluorouracil
::*Gemcitabine Hydrochloride
::*Gemzar (Gemcitabine Hydrochloride)
::*Mitomycin C
::*Mitozytrex (Mitomycin C)
::*Mutamycin (Mitomycin C)
::*Paclitaxel Albumin-stabilized Nanoparticle Formulation
::*Sunitinib Malate
::*Sutent (Sunitinib Malate)
::*Tarceva (Erlotinib Hydrochloride)
 
:*Drug Combinations Used in Pancreatic Cancer
::*FOLFIRINOX
::*GEMCITABINE-CISPLATIN
::*GEMCITABINE-OXALIPLATIN
::*OFF(Oxaliplatin,Fluorouracil and Folinic Acid)


===Nutritional supplements===
===Nutritional supplements===

Revision as of 18:26, 20 August 2015

Pancreatic cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Pancreatic Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic study of choice

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pancreatic cancer medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pancreatic cancer medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pancreatic cancer medical therapy

CDC on Pancreatic cancer medical therapy

Pancreatic cancer medical therapy in the news

Blogs on Pancreatic cancer medical therapy

Directions to Hospitals Treating Pancreatic cancer

Risk calculators and risk factors for Pancreatic cancer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

The selection of a treatment intervention depends largely on the disease progression and the patient's stage of cancer. Chemotherapy may be employed when surgical intervention is not deemed appropriate.


Medical Therapy

  • There are five different types of treatment for patients with pancreatic cancer.
  • Surgery
  • Radiation therapy
  • Chemotherapy
  • Chemoradiation therapy
  • Targeted therapy
  • New types of treatment are being tested in clinical trials.
  • Biologic therapy

Chemotherapy

  • Drugs Approved for Pancreatic Cancer
  • Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)
  • Adrucil (Fluorouracil)
  • Afinitor (Everolimus)
  • Efudex (Fluorouracil)
  • Erlotinib Hydrochloride
  • Everolimus
  • Fluoroplex (Fluorouracil)
  • Fluorouracil
  • Gemcitabine Hydrochloride
  • Gemzar (Gemcitabine Hydrochloride)
  • Mitomycin C
  • Mitozytrex (Mitomycin C)
  • Mutamycin (Mitomycin C)
  • Paclitaxel Albumin-stabilized Nanoparticle Formulation
  • Sunitinib Malate
  • Sutent (Sunitinib Malate)
  • Tarceva (Erlotinib Hydrochloride)
  • Drug Combinations Used in Pancreatic Cancer
  • FOLFIRINOX
  • GEMCITABINE-CISPLATIN
  • GEMCITABINE-OXALIPLATIN
  • OFF(Oxaliplatin,Fluorouracil and Folinic Acid)

Nutritional supplements

A phase II clinical trial studying the effect of curcumin on pancreatic cancer was completed in 2007 and the results were published in 2008. The study used eight grams per day in 21 patients and stopped treatment if the tumor size increased. The conclusion of the study was "Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer."[1][2]

Radiation Therapy

The role of radiotherapy as an auxiliary (adjuvant) treatment after potentially curative surgery has been controversial since the 1980s.[3] The European Society for Medical Oncology recommends that adjuvant radiotherapy should only be used for people enrolled in clinical trials.[4] However there is a continuing tendency for clinicians in the US to be more ready to use adjuvant radiotherapy than those in Europe. Many clinical trials have tested a variety of treatment combinations since the 1980s, but have failed to settle the matter conclusively.[3][5]

Radiotherapy may form part of treatment to attempt to shrink a tumor to a resectable state, but its use on unresectable tumors remains controversial as there are conflicting results from clinical trials. The preliminary results of one trial, presented in 2013, "markedly reduced enthusiasm" for its use on locally advanced tumors.[6]

References

  1. ↑ Dhillon N, Aggarwal BB, Newman RA; et al. (2008). "Phase II trial of curcumin in patients with advanced pancreatic cancer". Clin. Cancer Res. 14 (14): 4491–9. doi:10.1158/1078-0432.CCR-08-0024. PMID 18628464. Unknown parameter |month= ignored (help)
  2. ↑ De Leon D. "Cancer News and Information: Curcumin Temporarily Slows Pancreatic Cancer". CancerWise.
  3. ↑ 3.0 3.1
  4. ↑
  5. ↑
  6. ↑


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Pancreatic_cancer_medical_therapy&oldid=1138069"